2
Orphan Designations
0 approved, 1 designated
1
FDA Approvals
Latest: RUBRACA (2016)
0
Active Trials
6
Rare Diseases
across 10 areas
0
News (30d)
Quiet
Clovis Oncology, Inc. is a company with 2 orphan drug designations across 6 rare diseases, including 1 FDA-approved therapy. gene therapy candidates in 2 diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| autoimmune disease, multisystem, infantile-onset, 2 | rociletinib | Des.TrialAppr. |
| keratosis palmoplantaris striata 2 | rociletinib | Des.TrialAppr. |
| malignant pancreatic neoplasm | 5'-O-(trans-9"-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine | Des.TrialAppr. |
| non-small cell lung carcinoma | rociletinib | Des.TrialAppr. |
| psoriasis 14, pustular | rociletinib | Des.TrialAppr. |
| xeroderma pigmentosum group A | rociletinib | Des.TrialAppr. |
50% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
2/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
50% of portfolio targets high unmet need diseases
8
overlap in 2+ diseases
2/6
candidate diseases
0
avg importance: 0
0
affecting portfolio